The expression of tumor-rejection antigen "MAGE" genes in human gastric carcinoma

Hiroshi Inoue, Masaki Mori, Masayuki Honda, Jian Li, Kenji Shibuta, Koushi Mimori, Hiroaki Ueo, Tsuyoshi Akiyoshi

Research output: Contribution to journalArticlepeer-review

105 Citations (Scopus)


Background & Aims The genes MAGE-1 and MAGE-3 both encode melanoma peptide antigens recognized by major histocompatibility complex-restricted cytotoxic T lymphocytes. The antigens may be a target for immunotherapy. There is, however, little information on the expression of these genes in gastric carcinomas. Therefore, the expression of MAGE genes in gastric carcinomas was evaluated. Methods The expression of MAGE-1, MAGE-2, and MAGE-3 genes in tumors and corresponding normal tissue specimens was studied using a reverse-transcription polymerase chain reaction. The results were analyzed according to clinicopathologic factors of the tumor. Results In the 68 gastric carcinomas studied, MAGE-1, MAGE-2, and MAGE-3 messenger RNA were detected in 41%, 31%, and 38%, respectively. Fifty percent of the gastric carcinomas expressed at least one of the MAGE genes. Messenger RNA for the three MAGE proteins was not detected in normal gastric tissue. MAGE gene expression in gastric carcinomas was not associated with a significant clincopathology of the tumor. However, gene expression was lower in mucinous carcinomas (3 of 10). Conclusions MAGE-1, MAGE-2, and MAGE-3 are expressed in a high percentage of gastric carcinomas. These tumor rejection antigens may provide tumor-specific targets for immunotherapy.

Original languageEnglish
Pages (from-to)1522-1525
Number of pages4
Issue number5
Publication statusPublished - Nov 1995

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology


Dive into the research topics of 'The expression of tumor-rejection antigen "MAGE" genes in human gastric carcinoma'. Together they form a unique fingerprint.

Cite this